We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer

News   Jan 21, 2008

 
BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
 
 
Advertisement
 

RELATED ARTICLES

Study Indicates a Lack of Diversity in COVID-19 Clinical Trials

News

Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials, according to a new study.

READ MORE

Team Develops Synthetic Blood-Thinner With No Bleeding Side Effects

News

Scientists have developed a highly selective and highly stable synthetic blood-thinning molecule that, unlike others, doesn’t cause bleeding adverse effects.

READ MORE

RLF-100 Trial Shows Rapid Recovery From Respiratory Failure in Critically Ill Patients With COVID-19

News

A clinical trial of RLF-100 (aviptadil) has shown rapid recovery from respiratory failure in critically ill patients with COVID-19.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE